Business
Belluscura plc filing of a patent
Belluscura plc filing of a patent.
About this update from Tekcapital Plc
[{"type":"text","content":"\n \n \n RNS Number : 2544G\n Tekcapital plc\n 16 March 2020\n \n \n \n \n \n \n \n \n \n \n The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 (\"MAR\"). With the publication of this announcement via a Regulatory Information Service (\"RIS\"), this inside information is now considered to be in the public domain.\n \n \n \n \n \n 16 March 2020\n \n \n \n \n \n Tekcapital plc\n \n \n (\"Tekcapital\" or the \"Company\")\n \n \n Portfolio Company Update\n \n \n Belluscura plc announced the filing of a patent application on a modular,\n \n \n portable oxygen enrichment ventilation system\n \n \n Tekcapital plc, (AIM: TEK) the UK intellectual property investment group focused on creating marketplace value from investing in university technology, announces that its portfolio company Belluscura plc in conjunction with its exclusive research partner Separation Design Group, announced today the filing of a patent application covering novel modular portable oxygen enrichment ventilation systems for treating patients suffering from chronic obstructive pulmonary diseases (COPD) and acute respiratory distress syndrome (ARDS) brought on by such diseases as COVID-19.\n \n \n This latest patent application covers devices and systems for treating people suffering from COPD and ARDS including patients suffering from the recent coronavirus, COVID-19. The primary cause of death from respiratory viruses like the coronavirus and influenza, are the result of the fluids accumulating inside the alveoli (the tiny air sacs of the lungs) which ultimately leads to the failure of the transfer of oxygen to and carbon dioxide out of the blood. The current primary treatment for ARDS is oxygen therapy along with ventilator support.\n \n \n Belluscura and Separation Design are rapidly designing and developing next generation, cost-effective, portable oxygen enrichment and ventilation technology to treat COPD and ARDS patients. \n \n \n Commenting on the patenting activities, Bob Rauker, CEO of Belluscura, said: \"We are very excited about our next generation oxygen technologies. With the launch this year of our first product, the X-PLOR™ portable oxygen concentrator, into the respi...